<DOC>
	<DOCNO>NCT01529307</DOCNO>
	<brief_summary>This study ass safety , tolerability , maximum tolerate dose recommend dose expansion TAS266 administer IV infusion patient advance solid tumor .</brief_summary>
	<brief_title>First Human Trial TAS266 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Confirmed diagnosis solid tumor 18 year old ECOG performance status 0 , 1 2 Adequate bone marrow , hepatic renal function Obtained write informed consent Patients primary CNS tumor CNS tumor involvement . However patient CNS metastasis may allow certain condition meet . Major surgery within 4 week study treatment Prior anaphylactic severe infusion reaction human immunoglobulin antibody formulation Impaired cardiac function Previous hepatitis viral infection hepatitis B hepatitis C Diagnosis HIV infection Pregnant nursing ( lactate ) woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Biologic ,</keyword>
	<keyword>solid tumor ,</keyword>
	<keyword>Death Receptor 5 agonist ,</keyword>
	<keyword>caspase-8</keyword>
</DOC>